Andrés Gassert

Andres Gassert is an economist and seasoned industry expert who has held corporate strategy positions at multinational companies, including Bayer, Teva, and STADA (Cinven/BainCapital). 

His focus has been on M&A, Business Development & Licensing, market analysis, and advising on corporate strategy portfolios valued at over $1.5 billion. His biggest project hasbeen advising Cinven/Bain Capital on the sell of STADA for $8.5 billion to US-Private Equity. Andres has been active in the biotechnology industry, contributing to the first major techtransfer of monoclonal antibodies from private to public/private partnerships.

Since 2021, he has been working as an investment advisor to a Swiss Foundation through ObserVa Capital on public/private investments in Europe, including Sustainable Aviation Fuel, Energy Transition, Energy Storage, Biotechnology, Healthcare and Health-tech. His role involves delivering investment advice, due diligence, market analysis, while advising on corporate governance structure for invested startups in the United Kingdom.